While the previous PATHFINDER study—a prospective, year-long examination of about 6,600 people—showed that Galleri could more ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

Against an increasingly uncertain market backdrop, industry analysts EY said they are keeping an eye on potential ...

Back in May 2025, dapiglutide failed to impress in a phase 2 trial, mustering up to an average 4.3% reduction in weight loss when given at the 6 mg dose. The 54-person study involved administering ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a ...